Find a Clinical Trial

Showing 21 - 26 of 26 Trials

  • The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02693535

    Population:

    Adult

    Phase:

    II
    Many research studies are done to try to find the best way to treat patients with cancer. Researchers are working on new anticancer agents that are targeted to the genes in a person’s tumor. Genes are the basic “instruction book” for the cells that make up our bodies and are made out of DNA. DNA contains information that determines things such as eye and hair color. DNA is made up of long strands of repeating letters that form a code. The order of these letters in DNA is important. In the same way that a spelling mistake in a word could change its meaning (for example, mean...

  • Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04972110

    Population:

    Adult

    Phase:

    I/II
    The study is being done to learn how safe and effective the study drug, RP- 3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of drugs called ATR inhibitors that are design to stop cancer cells from growing. Are you Eligible? (Inclusion Criteria) Aged 18 years or older. Diagnosed with locally advanced or metastatic cancer. Have not received prior therapy with another...

  • A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04960787

    Population:

    Adult

    Phase:

    NA
    Studies have shown that cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment. This study is being done to answer the following question: Can a financial navigation program help patients and their spouses understand and better manage the financial aspects of cancer care? A financial navigator is a person or team who work with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health...

  • A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

    Principal Investigator:

    June Y. Hou, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02922764

    Population:

    Adult

    Phase:

    I
    The main purpose of this study is learn about the the safety and side effects of the study drug, RGX-104. RGX-104 is an experimental drug. This means that RGX-104 is not approved by the Food and Drug Administration (FDA). This is the first time RGX-104 will be given to humans. Are you Eligible? (Inclusion Criteria) Do you have a confirmed solid tumor? Have you had treatment for your disease before? Or is there not a standard treatment available for your disease? Does your cancer continue to grow? Can your cancer not be removed by surgery? Are you 18 years of age or older?

  • A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

    Principal Investigator:

    Hua-Jay J Cherng, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05279300

    Population:

    Adult

    Phase:

    I
    This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency for the treatment of any condition. It is only available in clinical studies such as this one. To date, it has only been tested in animal studies. This is the first time that the study drug will be given to humans. Are you Eligible? (Inclusion Criteria) Are you at least...

  • Trial of a Smartphone Application to Improve Medication Adherence among Patients with Cancer

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to learn about the difficulties patients have with the amount of medication they are required to take and to see if a smart phone application can make that process easier for patients. Patients will be asked to use an application on their smartphone or tablet daily and to come to the clinic once a month for 3 months. Are you Eligible? (Inclusion Criteria) Do you have advanced or metastatic cancer, or a hematologic malignancy? Are you taking, or planning to take at least one oral anti-cancer drug? Do you have access to a mobile phone or tablet that can download...

Pages